Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Vestager, ML; Hansen, ML; Rasmussen, MI; Hahn, GH; Hyttel-Sørensen, S; Pellicer, A; Heuchan, AM; Hagmann, C; Dempsey, E; Dimitriou, G; Pichler, G; Naulaers, G; Fuchs, H; Tkaczyk, J; Mintzer, J; Fumagalli, M; Nesargi, S; Fredly, S; Szczapa, T; Gluud, C; Jakobsen, JC; Greisen, G.
The effects of cerebral oximetry in mechanically ventilated newborns: a protocol for the SafeBoosC-IIIv randomised clinical trial.
TRIALS. 2023; 24(1): 696
Doi: 10.1186/s13063-023-07699-x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Pichler Gerhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The SafeBoosC project aims to test the clinical value of non-invasive cerebral oximetry by near-infrared spectroscopy in newborn infants. The purpose is to establish whether cerebral oximetry can be used to save newborn infants' lives and brains or not. Newborns contribute heavily to total childhood mortality and neonatal brain damage is the cause of a large part of handicaps such as cerebral palsy. The objective of the SafeBoosC-IIIv trial is to evaluate the benefits and harms of cerebral oximetry added to usual care versus usual care in mechanically ventilated newborns. METHODS/DESIGN: SafeBoosC-IIIv is an investigator-initiated, multinational, randomised, pragmatic phase-III clinical trial. The inclusion criteria will be newborns with a gestational age more than 28 + 0 weeks, postnatal age less than 28 days, predicted to require mechanical ventilation for at least 24 h, and prior informed consent from the parents or deferred consent or absence of opt-out. The exclusion criteria will be no available cerebral oximeter, suspicion of or confirmed brain injury or disorder, or congenital heart disease likely to require surgery. A total of 3000 participants will be randomised in 60 neonatal intensive care units from 16 countries, in a 1:1 allocation ratio to cerebral oximetry versus usual care. Participants in the cerebral oximetry group will undergo cerebral oximetry monitoring during mechanical ventilation in the neonatal intensive care unit for as long as deemed useful by the treating physician or until 28 days of life. The participants in the cerebral oximetry group will be treated according to the SafeBoosC treatment guideline. Participants in the usual care group will not receive cerebral oximetry and will receive usual care. We use two co-primary outcomes: (1) a composite of death from any cause or moderate to severe neurodevelopmental disability at 2 years of corrected age and (2) the non-verbal cognitive score of the Parent Report of Children's Abilities-Revised (PARCA-R) at 2 years of corrected age. DISCUSSION: There is need for a randomised clinical trial to evaluate cerebral oximetry added to usual care versus usual care in mechanically ventilated newborns. TRIAL REGISTRATION: The protocol is registered at www. CLINICALTRIALS: gov (NCT05907317; registered 18 June 2023).
- Find related publications in this database (using NLM MeSH Indexing)
- Infant - administration & dosage
- Child - administration & dosage
- Infant, Newborn - administration & dosage
- Humans - administration & dosage
- Oximetry - methods
- Respiration, Artificial - adverse effects
- Cerebrovascular Circulation - administration & dosage
- Brain - administration & dosage
- Intensive Care Units, Neonatal - administration & dosage
- Randomized Controlled Trials as Topic - administration & dosage
- Find related publications in this database (Keywords)
- Randomised clinical trial
- Near infrared spectroscopy
- Protocol
- Mechanical ventilation
- Brain injury